Denosumab is a monoclonal antibody that is designed to stop the bone cells responsible for removal of old bone.
There are two types of bone cells, bone building cells and bone breaking cells
Drugs and supplements can either impact the bone builders or bone breakers. Most drugs prevent the bone breaking cells from inhibiting the removal of old brittle bones. Denosumbab is no different.
The natural approach to improving fracture risk is to promote new bone repair rather than removal of old bone
Denosumab may improve bone density, but like other drugs, it may do so at the risk of building up poor quality bone